CRISPR has emerged as a promising alternative to viral-based gene editing by allowing scientists to modify genes with unprecedented ease and flexibility.
The discovery and development of a diverse range of CRISPR enzymes, each with its own specificities and modalities (such as CAS-9, CAS-12, CAS-13, and others), is a testament to the robustness of this technology. The new developments in Base and Prime editing further enhance the performance of CRISPR-based technologies, increasing their specificity and efficiency.
GenScript has an extensive portfolio of high-quality services and products for CRISPR gene editing.
In this webinar, we will discuss GenScript's CRISPR solutions for the different stages of the therapeutics development process, from discovery to lead generation and optimization, as well as pre-clinical and clinical development.
Learning Objectives:
Compare the advantages and disadvantages of each modality
Discover the complete toolbox of technologies available from GenScript